Drug Trial Radar · NCT05630833
A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
380
Actual
Start
Jan 11, 2023
Primary completion
Feb 2, 2024
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the consistency of therapeutic response of gepotidacin in female participants with acute uncomplicated cystitis with qualifying bacterial uropathogen(s) at baseline that all are susceptible to nitrofurantoin in Japan, with that from global studies (Studies 204989 \[NCT04020341\] and 212390 \[NCT04187144\]).
Conditions
- Urinary Tract Infections
Interventions
GepotidacinDrug
Gepotidacin will be administered.
NitrofurantoinDrug
Nitrofurantoin will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Therapeutic Response (TR) (Combined Per-participant Microbiological and Clinical Success) for Gepotidacin at the Test of Cure (TOC) VisitTime frame: At TOC visit (Days 9 to 16)
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Kagoshima, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kochi, Japan
GSK Investigational Site
Miyagi, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Saga, Japan
GSK Investigational Site
Saitama, Japan
GSK Investigational Site
Saitama, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.